Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas

Neuro-Oncology

Volumn 12, Issue 6, 2010, Pages 540-548

  Liu, Bo Lin ^a   Cheng, Jin Xiang ^a   Zhang, Wei ^a   Zhang, Xiang ^a   Wang, Rui ^b   Lin, Hong ^a   Huo, Jun Li ^a   Cheng, Hong ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Health Statistics ^*  (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Body fluids; Epigenetic biomarker; Glioma; Prognosis; Promoter methylation

Indexed keywords

CARMUSTINE; DNA; DNA METHYLTRANSFERASE; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; BODY FLUID; BRAIN TUMOR; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE; GLIOBLASTOMA; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METHYLATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; SERUM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 77957058258     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop064     Document Type: Article

References (30)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization Classification of Tumours of the Central Nervous System. Lyon: IARC Press;2007.
2. Central Brain Tumor Registry US. Central Brain Tumor Registry of the United States (2008) Statistical report: Primary Brain Tumors in the United States 2000-2004 (Years Data Collected). http://wwwcbtrusorg/reports/2007-2008/ 2007reportpdf 2008.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
4. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95:11891-11896.
5. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 2004;10:2284-2288. (Pubitemid 38445685)
6. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 2002;62:371-375.
7. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylationspecific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23:6569-6575.
8. Goessl C, Muller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci. 2001;945:51-58. (Pubitemid 33022431)
9. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. 2006;12:3306-3310.
10. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999;59:3251-3256. (Pubitemid 29316030)
11. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoterspecific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37:853-862.
12. Boehm D, Herold S, Kuechler A, Liehr T, Laccone F. Rapid detection of subtelomeric deletion/duplication by novel real-time quantitative PCR using SYBR-green dye. Hum Mutat. 2004;23:368-378.
13. Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64:1263-1269.
14. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-2710.
15. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005;45:629-656.
16. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50:6119-6129.
17. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
18. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
19. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003;144:134-142.
20. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003.
21. Lavon I, Zrihan D, Zelikovitch B, et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 2007;13:1429-1437.
22. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-4199.
23. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12:328-331.
24. Soejima H, ZhaoW, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol. 2005;83:429-437.
25. Oue N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006;106:1250-1259.
26. Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996;56:2405-2410.
27. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798-802.
28. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 1996;10:1183-1191.
29. Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene. 1999;18:3284-3289.
30. Rakyan VK, Hildmann T, Novik KL, et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol. 2004;2:e405.